8-K: Acurx Pharmaceuticals Faces Nasdaq Delisting Threat Due to Stockholders' Equity Shortfall

Acurx Pharmaceuticals received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Summary

• Acurx Pharmaceuticals received a notice from Nasdaq on March 25, 2025, indicating non-compliance with the minimum stockholders' equity requirement for continued listing.
• Nasdaq Listing Rule 5550(b)(1) mandates a minimum stockholders' equity of $2,500,000 for companies with a market value of listed securities less than $35,000,000 and annual net income less than $500,000.
• Acurx has until May 9, 2025, to submit a plan to regain compliance.
• If the plan is accepted, Nasdaq may grant an extension of 180 days from the date of the notice to regain compliance.
• There is no guarantee that the compliance plan will be accepted or that Acurx will be able to regain compliance.
• The notice does not immediately affect the company's listing, pending compliance with other requirements.
• If the compliance plan is rejected, Acurx may appeal to a Nasdaq Hearing Panel.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance. The company's future is uncertain.

Positives

• Acurx has the opportunity to submit a compliance plan to Nasdaq.
• Nasdaq may grant an extension of 180 days if the plan is accepted.
• The notice does not immediately affect the company's listing.

Negatives

• Acurx is not in compliance with Nasdaq's minimum stockholders' equity requirement.
• The company faces potential delisting from the Nasdaq Capital Market.
• There is no guarantee that the compliance plan will be accepted.

Risks

• Failure to submit an acceptable compliance plan could lead to delisting.
• Even with an accepted plan, Acurx may not be able to regain compliance within the given timeframe.
• Delisting could negatively impact the company's stock price and access to capital.

Future Outlook

The company must submit a plan to regain compliance with Nasdaq listing requirements, but there is no assurance that the plan will be accepted or that the company will be able to regain compliance.

Management Comments

• David P. Luci, President and Chief Executive Officer, signed the report on behalf of Acurx Pharmaceuticals.

Industry Context

Delisting notices are not uncommon for small-cap pharmaceutical companies, especially those with limited revenue and ongoing research and development expenses. Companies in similar situations often explore options such as reverse stock splits, raising additional capital, or seeking strategic alternatives.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain Nasdaq compliance, especially during periods of high research and development spending and limited product revenue.
• Companies like Acurx often compare themselves to peers in the microbiome therapeutics space, such as Seres Therapeutics or Finch Therapeutics, but these companies typically have significantly higher market capitalizations and access to funding.
• The $2.5 million stockholders' equity requirement is a standard benchmark for Nasdaq Capital Market listing, and failure to meet this threshold is a common reason for delisting notices.

Stakeholder Impact

• Shareholders may experience a decline in stock value if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's ability to raise capital and fund research and development may be negatively impacted.

Next Steps

• Acurx must submit a compliance plan to Nasdaq by May 9, 2025.
• Nasdaq will review the plan and determine whether to grant an extension.
• Acurx may need to take steps to increase its stockholders' equity.

Key Dates

Keywords

Delisting, Nasdaq, Stockholders' Equity, Compliance, Acurx Pharmaceuticals, Listing Rule